#Japan #Tokyo #Drug Discovery #Sumitomo Pharma #Zeureka

Collaboration for Drug Development

Zeureka Inc., located in Minato-ku, Tokyo, has announced a joint research agreement with Sumitomo Pharma Co., Ltd., based in Osaka. This partnership aims to enhance the discovery of low-molecular compounds targeting specific areas identified by Sumitomo Pharma. The two companies will collaborate in the design and evaluation of these novel compounds to bring forth new drug candidates.

Zeureka is poised to utilize its advanced computational drug discovery technologies, including its proprietary Free Energy Perturbation (FEP) program, known as “Xeureka FEP,” combined with its molecule generation tool, “XE-Generator.” This strategic leverage of high-end technology promises to accelerate the research and development phases, significantly boosting the chances of success for new therapeutics.

In this joint venture, Zeureka's robust computing power, supported by large-scale supercomputers and cutting-edge computational methodologies like AI and extensive molecular dynamics simulations, will be key. The company's goal remains to provide comprehensive drug discovery support services that cater to the diverse needs of pharmaceutical and biotech companies.

The Free Energy Perturbation (FEP) technique is a statistically grounded method used to calculate changes in free energy associated with the binding of ligands to proteins, enabling high-accuracy predictions of biological activity. This approach will be instrumental in determining the efficacy and stability of various compound structures developed throughout the research process.

On the other hand, Xeureka's XE-Generator stands at the forefront of their drug discovery tools. This innovative molecular generation tool is built around over 6,000 meticulously curated structural transformation rules, shaped by the expertise of seasoned medicinal chemists in the pharmaceutical field. It employs techniques such as Matched Molecular Pair (MMP) based structural transformation and bioisostere replacement. By using this tool, researchers can effectively generate a vast range of practical compound structures, allowing for a more exhaustive exploration of feasible therapeutic candidates.

Zeureka, founded in November 2021 and wholly owned by Mitsui & Co., is dedicated to transforming drug discovery processes. Its initiatives not only focus on pharmaceutical innovations but also aim to streamline research efforts across the industry. The company strives to enhance the efficiency of drug development and improve overall success rates by harnessing the synergistic potential of computational chemistry and AI technologies.

In summary, this alliance between Zeureka and Sumitomo Pharma symbolizes a progressive step in the pharmaceutical sector, as both firms share the common mission of creating new healthcare solutions through innovative drug discovery practices. As they embark on this joint research initiative, the impact of their collaboration is anticipated to reflect significantly in the coming years, potentially leading to breakthroughs that may alter the landscape of medical treatments.

For more information on Zeureka and its unique offerings, visit Zeureka Official Website. Similarly, to learn more about Sumitomo Pharma's innovative approach to medicine, check their website at Sumitomo Pharma Official Website.